EBNA3C Augments Pim-1 Mediated Phosphorylation and Degradation of p21 to Promote B-Cell Proliferation

1. HenleG, HenleW, CliffordP, DiehlV, KafukoGW, et al. (1969) Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst 43: 1147–1157.

2. JangHS, ChoJO, YoonCY, KimHJ, ParkJC (2001) Demonstration of Epstein-Barr virus in odontogenic and nonodontogenic tumors by the polymerase chain reaction (PCR). J Oral Pathol Med 30: 603–610.

3. Raab-TraubN (2002) Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 12: 431–441.

4. OremJ, MbiddeEK, LambertB, de SanjoseS, WeiderpassE (2007) Burkitt's lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci 7: 166–175.

5. NourseJP, JonesK, GandhiMK Epstein-Barr Virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy. Am J Transplant 11: 888–895.

6. HsuJL, GlaserSL (2000) Epstein-barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit Rev Oncol Hematol 34: 27–53.

7. CesarmanE, MesriEA (1999) Virus-associated lymphomas. Curr Opin Oncol 11: 322–332.

8. TokunagaM, LandCE, UemuraY, TokudomeT, TanakaS, et al. (1993) Epstein-Barr virus in gastric carcinoma. Am J Pathol 143: 1250–1254.

9. HenleW, DiehlV, KohnG, Zur HausenH, HenleG (1967) Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells. Science 157: 1064–1065.

10. YoungLS, DawsonCW, EliopoulosAG (2000) The expression and function of Epstein-Barr virus encoded latent genes. Mol Pathol 53: 238–247.

11. PaschosK, SmithP, AndertonE, MiddeldorpJM, WhiteRE, et al. (2009) Epstein-barr virus latency in B cells leads to epigenetic repression and CpG methylation of the tumour suppressor gene Bim. PLoS Pathog 5: e1000492.

12. ZhaoB, MarJC, MaruoS, LeeS, GewurzBE, et al. Epstein-Barr virus nuclear antigen 3C regulated genes in lymphoblastoid cell lines. Proc Natl Acad Sci U S A 108: 337–342.

13. MaruoS, ZhaoB, JohannsenE, KieffE, ZouJ, et al. Epstein-Barr virus nuclear antigens 3C and 3A maintain lymphoblastoid cell growth by repressing p16INK4A and p14ARF expression. Proc Natl Acad Sci U S A 108: 1919–1924.

14. SubramanianC, KnightJS, RobertsonES (2002) The Epstein Barr nuclear antigen EBNA3C regulates transcription, cell transformation and cell migration. Front Biosci 7: d704–716.

15. RobertsonES, LinJ, KieffE (1996) The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J Virol 70: 3068–3074.

16. AlldayMJ, FarrellPJ (1994) Epstein-Barr virus nuclear antigen EBNA3C/6 expression maintains the level of latent membrane protein 1 in G1-arrested cells. J Virol 68: 3491–3498.

17. KnightJS, LanK, SubramanianC, RobertsonES (2003) Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol 77: 4261–4272.

18. SubramanianC, RobertsonES (2002) The metastatic suppressor Nm23-H1 interacts with EBNA3C at sequences located between the glutamine- and proline-rich domains and can cooperate in activation of transcription. J Virol 76: 8702–8709.

19. CaiQ, GuoY, XiaoB, BanerjeeS, SahaA, et al. Epstein-Barr virus nuclear antigen 3C stabilizes Gemin3 to block p53-mediated apoptosis. PLoS Pathog 7: e1002418.

20. BajajBG, MurakamiM, CaiQ, VermaSC, LanK, et al. (2008) Epstein-Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. J Virol 82: 4082–4090.

21. YiF, SahaA, MurakamiM, KumarP, KnightJS, et al. (2009) Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 388: 236–247.

22. SahaA, HalderS, UpadhyaySK, LuJ, KumarP, et al. Epstein-Barr virus nuclear antigen 3C facilitates G1-S transition by stabilizing and enhancing the function of cyclin D1. PLoS Pathog 7: e1001275.

23. BraultL, GasserC, BracherF, HuberK, KnappS, et al. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 95: 1004–1015.

24. HuXF, LiJ, VandervalkS, WangZ, MagnusonNS, et al. (2009) PIM-1-specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest 119: 362–375.

25. HuYL, PassegueE, FongS, LargmanC, LawrenceHJ (2007) Evidence that the Pim1 kinase gene is a direct target of HOXA9. Blood 109: 4732–4738.

26. AmsonR, SigauxF, PrzedborskiS, FlandrinG, GivolD, et al. (1989) The human protooncogene product p33pim is expressed during fetal hematopoiesis and in diverse leukemias. Proc Natl Acad Sci U S A 86: 8857–8861.

27. MuraskiJA, RotaM, MisaoY, FransioliJ, CottageC, et al. (2007) Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 13: 1467–1475.

28. EichmannA, YuanL, BreantC, AlitaloK, KoskinenPJ (2000) Developmental expression of pim kinases suggests functions also outside of the hematopoietic system. Oncogene 19: 1215–1224.

29. GapterLA, MagnusonNS, NgKY, HosickHL (2006) Pim-1 kinase expression during murine mammary development. Biochem Biophys Res Commun 345: 989–997.

30. MoroyT, GrzeschiczekA, PetzoldS, HartmannKU (1993) Expression of a Pim-1 transgene accelerates lymphoproliferation and inhibits apoptosis in lpr/lpr mice. Proc Natl Acad Sci U S A 90: 10734–10738.

31. SarisCJ, DomenJ, BernsA (1991) The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J 10: 655–664.

32. PalatyCK, KalmarG, TaiG, OhS, AmankawaL, et al. (1997) Identification of the autophosphorylation sites of the Xenopus laevis Pim-1 proto-oncogene-encoded protein kinase. J Biol Chem 272: 10514–10521.

33. PalatyCK, Clark-LewisI, LeungD, PelechSL (1997) Phosphorylation site substrate specificity determinants for the Pim-1 protooncogene-encoded protein kinase. Biochem Cell Biol 75: 153–162.

34. BullockAN, DebreczeniJ, AmosAL, KnappS, TurkBE (2005) Structure and substrate specificity of the Pim-1 kinase. J Biol Chem 280: 41675–41682.

35. WangZ, BhattacharyaN, MixterPF, WeiW, SedivyJ, et al. (2002) Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 1593: 45–55.

36. ZhangY, WangZ, MagnusonNS (2007) Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res 5: 909–922.

37. MochizukiT, KitanakaC, NoguchiK, MuramatsuT, AsaiA, et al. (1999) Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem 274: 18659–18666.

38. WangZ, BhattacharyaN, MeyerMK, SeimiyaH, TsuruoT, et al. (2001) Pim-1 negatively regulates the activity of PTP-U2S phosphatase and influences terminal differentiation and apoptosis of monoblastoid leukemia cells. Arch Biochem Biophys 390: 9–18.

39. BhattacharyaN, WangZ, DavittC, McKenzieIF, XingPX, et al. (2002) Pim-1 associates with protein complexes necessary for mitosis. Chromosoma 111: 80–95.

40. BachmannM, HennemannH, XingPX, HoffmannI, MoroyT (2004) The oncogenic serine/threonine kinase Pim-1 phosphorylates and inhibits the activity of Cdc25C-associated kinase 1 (C-TAK1): a novel role for Pim-1 at the G2/M cell cycle checkpoint. J Biol Chem 279: 48319–48328.

41. BachmannM, KosanC, XingPX, MontenarhM, HoffmannI, et al. (2006) The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol 38: 430–443.

42. PircherTJ, ZhaoS, GeigerJN, JonejaB, WojchowskiDM (2000) Pim-1 kinase protects hematopoietic FDC cells from genotoxin-induced death. Oncogene 19: 3684–3692.

43. BajajBG, VermaSC, LanK, CotterMA, WoodmanZL, et al. (2006) KSHV encoded LANA upregulates Pim-1 and is a substrate for its kinase activity. Virology 351: 18–28.

44. KimJH, KimWS, YunY, ParkC Epstein-Barr virus latent membrane protein 1 increases chemo-resistance of cancer cells via cytoplasmic sequestration of Pim-1. Cell Signal 22: 1858–1863.

45. RainioEM, AhlforsH, CarterKL, RuuskaM, MatikainenS, et al. (2005) Pim kinases are upregulated during Epstein-Barr virus infection and enhance EBNA2 activity. Virology 333: 201–206.

46. SahaA, LuJ, MorizurL, UpadhyaySK, AjMP, et al. E2F1 mediated apoptosis induced by the DNA damage response is blocked by EBV nuclear antigen 3C in lymphoblastoid cells. PLoS Pathog 8: e1002573.

47. MaundersMJ, PettiL, RoweM (1994) Precipitation of the Epstein-Barr virus protein EBNA 2 by an EBNA 3c-specific monoclonal antibody. J Gen Virol 75 (Pt 4): 769–778.

48. PeltolaK, HollmenM, MaulaSM, RainioE, RistamakiR, et al. (2009) Pim-1 kinase expression predicts radiation response in squamocellular carcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia 11: 629–636.

49. WalpenT, KalusI, SchwallerJ, PeierMA, BattegayEJ, et al. Nuclear PIM1 confers resistance to rapamycin-impaired endothelial proliferation. Biochem Biophys Res Commun 429: 24–30.

50. SahaA, MurakamiM, KumarP, BajajB, SimsK, et al. (2009) Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol 83: 4652–4669.

51. BanerjeeS, LuJ, CaiQ, SahaA, JhaHC, et al. The EBV Latent Antigen 3C Inhibits Apoptosis through Targeted Regulation of Interferon Regulatory Factors 4 and 8. PLoS Pathog 9: e1003314.

52. KnightJS, SharmaN, RobertsonES (2005) Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci U S A 102: 18562–18566.

53. HsiED, JungSH, LaiR, JohnsonJL, CookJR, et al. (2008) Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study. Leuk Lymphoma 49: 2081–2090.

54. MahadevanD, SpierC, Della CroceK, MillerS, GeorgeB, et al. (2005) Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures. Mol Cancer Ther 4: 1867–1879.

55. AhoTL, SandholmJ, PeltolaKJ, MankonenHP, LillyM, et al. (2004) Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 571: 43–49.

56. ChenXP, LosmanJA, CowanS, DonahueE, FayS, et al. (2002) Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc Natl Acad Sci U S A 99: 2175–2180.

57. RainioEM, SandholmJ, KoskinenPJ (2002) Cutting edge: Transcriptional activity of NFATc1 is enhanced by the Pim-1 kinase. J Immunol 168: 1524–1527.

58. KoikeN, MaitaH, TairaT, ArigaH, Iguchi-ArigaSM (2000) Identification of heterochromatin protein 1 (HP1) as a phosphorylation target by Pim-1 kinase and the effect of phosphorylation on the transcriptional repression function of HP1(1). FEBS Lett 467: 17–21.

59. MaitaH, HaradaY, NagakuboD, KitauraH, IkedaM, et al. (2000) PAP-1, a novel target protein of phosphorylation by pim-1 kinase. Eur J Biochem 267: 5168–5178.

60. WangZ, BhattacharyaN, WeaverM, PetersenK, MeyerM, et al. (2001) Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2: 167–179.

61. AbbasT, DuttaA (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9: 400–414.

62. VlachostergiosPJ, VoutsadakisIA, PapandreouCN The ubiquitin-proteasome system in glioma cell cycle control. Cell Div 7: 18.

63. AmadorV, GeS, SantamariaPG, GuardavaccaroD, PaganoM (2007) APC/C(Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase. Mol Cell 27: 462–473.

64. DottoGP (2000) p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 1471: M43–56.

65. CoqueretO (2003) New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol 13: 65–70.

66. SherrCJ, RobertsJM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13: 1501–1512.

67. BessonA, DowdySF, RobertsJM (2008) CDK inhibitors: cell cycle regulators and beyond. Dev Cell 14: 159–169.

68. CottageCT, BaileyB, FischerKM, AvitableD, CollinsB, et al. Cardiac progenitor cell cycling stimulated by pim-1 kinase. Circ Res 106: 891–901.

69. WangJ, AndersonPD, LuoW, GiusD, RohM, et al. Pim1 kinase is required to maintain tumorigenicity in MYC-expressing prostate cancer cells. Oncogene 31: 1794–1803.

70. FuldaS, DebatinKM (2006) Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 25: 4798–4811.

71. FuldaS, DebatinKM (2004) Targeting apoptosis pathways in cancer therapy. Curr Cancer Drug Targets 4: 569–576.

72. GartelAL, RadhakrishnanSK (2005) Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65: 3980–3985.

73. ZhiX, ZhaoD, WangZ, ZhouZ, WangC, et al. E3 ubiquitin ligase RNF126 promotes cancer cell proliferation by targeting the tumor suppressor p21 for ubiquitin-mediated degradation. Cancer Res 73: 385–394.

74. CuypersHT, SeltenG, QuintW, ZijlstraM, MaandagER, et al. (1984) Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 37: 141–150.

75. SwordsR, KellyK, CarewJ, NawrockiS, MahalingamD, et al. The Pim kinases: new targets for drug development. Curr Drug Targets 12: 2059–2066.

76. IonovY, LeX, TunquistBJ, SweetenhamJ, SachsT, et al. (2003) Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res 23: 167–178.

77. HoefnagelJJ, DijkmanR, BassoK, JansenPM, HallermannC, et al. (2005) Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood 105: 3671–3678.

78. AyalaGE, DaiH, IttmannM, LiR, PowellM, et al. (2004) Growth and survival mechanisms associated with perineural invasion in prostate cancer. Cancer Res 64: 6082–6090.

79. BachmannM, MoroyT (2005) The serine/threonine kinase Pim-1. Int J Biochem Cell Biol 37: 726–730.

80. WhiteRE, GrovesIJ, TurroE, YeeJ, KremmerE, et al. Extensive co-operation between the Epstein-Barr virus EBNA3 proteins in the manipulation of host gene expression and epigenetic chromatin modification. PLoS One 5: e13979.

81. SkalskaL, WhiteRE, FranzM, RuhmannM, AlldayMJ Epigenetic repression of p16(INK4A) by latent Epstein-Barr virus requires the interaction of EBNA3A and EBNA3C with CtBP. PLoS Pathog 6: e1000951.

82. KaulR, MurakamiM, ChoudhuriT, RobertsonES (2007) Epstein-Barr virus latent nuclear antigens can induce metastasis in a nude mouse model. J Virol 81: 10352–10361.

83. KnightJS, SharmaN, KalmanDE, RobertsonES (2004) A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells. J Virol 78: 12857–12867.

84. MizunoK, ShiroganeT, ShinoharaA, IwamatsuA, HibiM, et al. (2001) Regulation of Pim-1 by Hsp90. Biochem Biophys Res Commun 281: 663–669.

85. ShayKP, WangZ, XingPX, McKenzieIF, MagnusonNS (2005) Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res 3: 170–181.

86. SahaA, RobertsonES Impact of EBV essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis. Future Microbiol 8: 323–352.

87. KnightJS, SharmaN, RobertsonES (2005) SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol 25: 1749–1763.

88. TouitouR, O'NionsJ, HeaneyJ, AlldayMJ (2005) Epstein-Barr virus EBNA3 proteins bind to the C8/alpha7 subunit of the 20S proteasome and are degraded by 20S proteasomes in vitro, but are very stable in latently infected B cells. J Gen Virol 86: 1269–1277.

89. JhaHCAJM, SahaA, BanerjeeS, LuJ, et al. Epstein-Barr virus essential antigen EBNA3C attenuates H2AX expression. J Virol 88: 3776–3788.

90. CenB, MahajanS, ZemskovaM, BeharryZ, LinYW, et al. Regulation of Skp2 levels by the Pim-1 protein kinase. J Biol Chem 285: 29128–29137.

91. SeltenG, CuypersHT, ZijlstraM, MeliefC, BernsA (1984) Involvement of c-myc in MuLV-induced T cell lymphomas in mice: frequency and mechanisms of activation. EMBO J 3: 3215–3222.

92. AmaravadiR, ThompsonCB (2005) The survival kinases Akt and Pim as potential pharmacological targets. J Clin Invest 115: 2618–2624.

93. BurkhartBA, AlcortaDA, ChiaoC, IsaacsJS, BarrettJC (1999) Two posttranscriptional pathways that regulate p21(Cip1/Waf1/Sdi1) are identified by HPV16-E6 interaction and correlate with life span and cellular senescence. Exp Cell Res 247: 168–175.

94. JarviluomaA, ChildES, SarekG, SirimongkolkasemP, PetersG, et al. (2006) Phosphorylation of the cyclin-dependent kinase inhibitor p21Cip1 on serine 130 is essential for viral cyclin-mediated bypass of a p21Cip1-imposed G1 arrest. Mol Cell Biol 26: 2430–2440.

95. O'NionsJ, AlldayMJ (2003) Epstein-Barr virus can inhibit genotoxin-induced G1 arrest downstream of p53 by preventing the inactivation of CDK2. Oncogene 22: 7181–7191.

96. ZhuN, RamirezLM, LeeRL, MagnusonNS, BishopGA, et al. (2002) CD40 signaling in B cells regulates the expression of the Pim-1 kinase via the NF-kappa B pathway. J Immunol 168: 744–754.

97. ChenJ, KobayashiM, DarmaninS, QiaoY, GullyC, et al. (2009) Pim-1 plays a pivotal role in hypoxia-induced chemoresistance. Oncogene 28: 2581–2592.

98. HernandezAM, ColvinES, ChenYC, GeissSL, EllerLE, et al. (2013) Upregulation of p21 activates the intrinsic apoptotic pathway in beta cells. Am J Physiol Endocrinol Metab 304: E1281–90.

99. LuJ, VermaSC, MurakamiM, CaiQ, KumarP, et al. (2009) Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus (KSHV) upregulates survivin expression in KSHV-Associated B-lymphoma cells and contributes to their proliferation. J Virol 83: 7129–7141.

100. HalderS, MurakamiM, VermaSC, KumarP, YiF, et al. (2009) Early events associated with infection of Epstein-Barr virus infection of primary B-cells. PLoS One 4: e7214.

101. LaemmliUK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685.

102. KimKT, BairdK, AhnJY, MeltzerP, LillyM, et al. (2005) Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 105: 1759–1767.